Announcement of the National Medical Insurance Administration on the Phase Results of the Application for Drug Expert Review of the National Medical Insurance Drug Directory Adjustment in 2022
In accordance with the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Directory Adjustment Work Plan", the National Medical Insurance Administration organized experts to conduct a comprehensive review of the application for drugs that passed the adjustment form of the National Basic Medical Insurance , Work Injury Insurance and Maternity Insurance Drug Directory (hereinafter referred to as the 2022 National Medical Insurance Drug Directory). At present, the expert review work has been completed. The announcement is as follows:
1. All applicant companies can log in to the "2022 National Medical Insurance Drug Catalog Adjustment Application" module (hereinafter referred to as the declaration module) to check the expert review results.
2. The evaluation results are drugs with "new additions to negotiate", "new additions to bid", "new extensions to negotiate", and "simple renewal". The corresponding enterprises download the corresponding "confirmation letter template" in the "application module". Please fill in and stamp the official seal as required and upload it to the "Report Module" before 17:00 on October 20, 2022, and send the original to the National Health Insurance Administration (postmark shall prevail).
3. Confirm the participation in the negotiation and confirm the participation in the bidding drugs. The corresponding company downloads the corresponding "reporting material template" in the "Declaration Module" and fills in and submits it as required. Enterprises must ensure that the relevant data and materials submitted are complete, true and reliable, and send one copy of the paper and electronic CD (the first volume of materials is provided with Word and PDF versions) to the National Health Insurance Administration (the postmark shall prevail) before 17:00 on November 3, 2022.
For negotiation/bidding reference drugs, negotiation main specifications and medical insurance payment scope determined by experts, please click "Details" in the "Negotiation/Bidding Information" column to view.
4. If the evaluation results are "newly proposed to negotiate" and "newly planned to bid", it means that the drug has been included in the negotiation/bidding scope of the 2022 National Medical Insurance Drug Catalog and has obtained negotiation/bidding qualifications, which does not mean that the drug has been included in the 2022 National Medical Insurance Drug Catalog.
5. In order to ensure the smooth progress of the subsequent stage of catalog adjustment, before the 2022 National Medical Insurance Drug Catalog is officially released, all applicants shall not publish any information about this adjustment.
Contact number: 010-89061448/1449 (October 17, 2022-November 3, 2022, working days 9:00-17:00)
Email: [email protected] (The email is named "enterprise name" + "drug name")
Mailing address: No. 2-9, Yuetan North Street, Xicheng District, Beijing Medical Insurance Bureau Medical Insurance Directory Adjustment Working Group Postal Code 100830
National Medical Insurance Bureau
October 15, 2022

Web page screenshot

Edit: Zhang Tianyi
Information: Xinhua News Agency